Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Israel / NCT05345613
Recruiting Phase 4

Tranexamic Acid During Colonic Endoscopic Resection Procedures

NCT05345613 · tracked via the Priya Life Science Israel tracker
Sponsor
Assaf-Harofeh Medical Center
Phase
Phase 4
Started
2022-05-01
Last updated
2026-01-13

Condition(s) studied

Colon Neoplasm

Investigational drug(s) / intervention(s)

Tranexamic acid →Standard

Tranexamic acid: Submucosal injection of standard solution including TXA during EMR procedure

Standard: Injection of standard solution

Study summary

Colonoscopy with polypectomy reduces the incidence and mortality associated with colon cancer. However, polypectomy is associated with adverse events such as bleeding. Tranexamic acid (TXA) is a synthetic derivative of lysine that exerts antifibrinolytic effects and may prevent bleeding. The investigators aim to evaluate the effect of local TXA on preventing intraprocedural and postprocedural bleeding in patients undergoing endoscopic mucosal resection (EMR) of large colon polyps.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients referred for endoscopic resection of non-neoplastic and neoplastic lesions in the colon presenting to our tertiary academic center. * Age \> 18 years Exclusion Criteria: * patients with histories of allergic reactions to TXA * history of seizures * pregnancy

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Shamir Medical Center Be’er Ya‘aqov Israel Recruiting

More Assaf-Harofeh Medical Center trials in Israel

Effect of Hyperoxygenated Environment on Maximal Muscle Strength Recruiting
Sensory Rehabilitation in Chemo Induced Peripheral Neuropathy Recruiting
Metabolic Changes Associated With Weight Gain After Treatment of Achalasia Starting soon
Hyperbaric Oxygen Therapy Used on Severely Injured Healthy Individuals With Fungal Infections Active, not recruiting
Cognitive Profile of Patients at the Sagol Center for Hyperbaric Medicine and Research Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05345613 on ClinicalTrials.gov ↗ ← All trials in Israel